ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Altered amino acids and acylcarnitines profile in infantile intrahepatic cholestasis liver disease: implication for Traditional Chinese Medicine syndrome differentiation.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo explore the diagnostic efficacy of blood amino acids (AAs) and acylcarnitines (ACs) profiles as metabolic biomarkers for differentiating Traditional Chinese Medicine (TCM) syndromes in infantile intrahepatic cholestatic liver disease (IICLD).
methodsBlood samples were collected from a cohort comprising 50 healthy controls and 77 patients diagnosed with IICLD, including 43 cases categorized as cold-damp obstruction and stagnation syndrome (COS) and 34 cases as jaundice due to stasis and accumulation syndrome (JSA) based on TCM diagnostic criteria. Metabolomic analyses targeting AAs and ACs were performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
resultsCompared with the healthy controls group, the IICLD group showed 23 upregulated and 2 downregulated metabolites with a screening threshold of variables of importance in projection (VIP) ≥ 1, fold change (FC) ≥ 1.2 or ≤ 0.83, and
conclusionDistinct alteration of AAs and ACs profile highlighted the oxidative stress and mitochondrial impairment in IICLD. A combined set of metabolites (Orn+ C10DC+ C6) emerged as valuable biomarker for differentiating between the COS syndrome and JSA syndromes, providing a biochemical basis for syndrome differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.